Generic Medicine Info
Indications and Dosage
Cerebrovascular and peripheral vascular disease
Adult: 10-20 mg 3 or 4 times daily.
May be taken with or without food. May be taken w/ meals, milk or antacids to minimise GI discomfort.
Recent arterial haemorrhage.
Special Precautions
Pregnancy and lactation. Not intended to be given immediately postpartum.
Adverse Reactions
Significant: Severe rash.
Nervous: Trembling, nervousness, weakness, dizziness.
CV: Palpitation, tachycardia, chest pain, hypotension, flushing.
GI: Abdominal distress, nausea, vomiting, intestinal distention.
IV/Parenteral/PO: C
Mechanism of Action: Isoxsuprine, a β-agonist, increases muscle blood flow by directly relaxing the vascular smooth muscle.
Absorption: Well absorbed from the GI tract. Time to peak plasma concentration: Approx 1 hr.
Distribution: Crosses the placenta.
Excretion: Excreted via urine as conjugates. Plasma elimination half-life: Approx 1.5 hr.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Isoxsuprine, CID=3783, (accessed on Jan. 21, 2020)

Store between 15-30°C.
MIMS Class
Peripheral Vasodilators & Cerebral Activators
ATC Classification
C04AA01 - isoxsuprine ; Belongs to the class of 2-amino-1-phenylethanol derivative agents. Used as peripheral vasodilators.
Anon. Isoxsuprine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 10/07/2017.

Buckingham R (ed). Isoxsuprine Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 10/07/2017.

Isoxsuprine Hydrochloride Tablets (Vista Pharmaceuticals, Inc.). DailyMed. Source: U.S. National Library of Medicine. Accessed 10/07/2017.

McEvoy GK, Snow EK, Miller J et al (eds). Isoxsuprine Hydrochloride. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 10/07/2017.

Disclaimer: This information is independently developed by MIMS based on Isoxsuprine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
  • Hystolan
  • Tonotan
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in